AMES, Iowa, Jan. 26 /PRNewswire-FirstCall/ -- BioForce Nanosciences, Inc., a wholly owned subsidiary of BioForce Nanosciences Holdings, Inc. , announced that it exceeded its 2006 goal for shipping up to 20 of its cutting-edge Nano eNabler(TM) molecular printers to prestigious institutions across the globe. BioForce exceeded its goal by two units by year end. These pilot placements of the Company’s patented Nano eNabler device at centers of research excellence, allow the entrepreneurial researchers at those centers to act as “early adopters” of BioForce’s practical tools and technologies.
“With the shipment of these 22 Nano eNabler molecular printers,” says BioForce Product Manager Michael Lynch, “BioForce is now essentially partnering with an impressive group of innovators working in the micro and nanotechnology fields. Several groups have already expressed a desire to seek funds to convert their placement into a purchase.”
Kerry Frey, BioForce’s chief operating officer, says, “BioForce Nanosciences is positioned between two very exciting markets-nanotechnology and the life sciences. We strongly believe our Nano eNabler system will change how research is conducted in laboratories across the world.” He explains that the ease of use and practicality provided by the Nano eNabler system, establish a path from laboratory to industry.
Institutions where recent placements have taken place: * University of California, Cal-it2, Irvine, CA * Cornell University, NanoBioTechnology Center, Ithaca, NY * ETH Zurich, Zurich, Switzerland * Georgia Institute of Technology, Microelectronics Research Center, Atlanta, GA * Stanford University, James H. Clark Center, Stanford, CA About BioForce Nanosciences, Inc.
BioForce Nanosciences, Inc. is a wholly owned subsidiary of BioForce Nanosciences Holdings, Inc. . BioForce Nanosciences is a unique company entering into commercialization with over a decade of research and accomplishment in the field of bionanotechnology. BioForce has demonstrated the ability to take a product from concept to commercial sale. For more information, visit http://www.bioforcenano.com.
This news release contains forward-looking information that may be affected by certain risks and uncertainties, including those risks and uncertainties described in the Company’s most recent filings with the Securities and Exchange Commission. The Company’s actual results could differ materially from such forward-looking statements. We assume no duty to update these statements at any future date.
BioForce Nanosciences, Inc.
CONTACT: Deb Happe, Director of Communications, +1-515-233-8333, Ext. 123,dhappe@bioforcenano.com
Web site: http://www.bioforcenano.com/
